SITRA
24.10.2016 14:49:39 CEST | Business Wire | Press release
The world is in serious need of solutions concerning how to sustainably create growth and jobs. A pioneering event will offer those solutions in June 2017 in Helsinki, Finland. The agenda features the world’s best circular economy solutions based on the implementation of the UN’s Sustainable Development Goals. The event is organised by Sitra together with a large group of global institutions.
Sitra is inviting the future shapers of our well-being to celebrate Finland’s 100th year of independence at the World Circular Economy Forum 2017 in Helsinki. The event (5-6 June 2017) brings together 1,200 international business and NGO leaders, managers, urban experts and government officials.
The focus of the event is on genuinely sustainable and competitive solutions for the circular economy – on solutions that have been created in different parts of the world and in which business and the environment go hand in hand. The circular economy plays an important role in the realisation of the UN’s Sustainable Development Goals.
”We will also explain how Finland, as the first country in the world, is implementing its national roadmap of the circular economy – how the whole society is increasing its competitiveness and benefiting from moving to a new operational model for the economy, a model in which the growth of the economy and well-being are no longer based on the overconsumption of natural resources and fossil fuels”, says Mari Pantsar , the director resource-wise and carbon-neutral activities in Sitra.
The group of most recognized speakers presenting diverse solutions for the circular economy at the World Circular Economy Forum covers a large spectrum of the world’s top experts. Among the participants are Achim Steiner , the former head of the UN’s Environment Programme; Jyrki Katainen , EU Commissioner; Ashok Khosla , Founder and President of Development Alternatives and Co-chair of the UN’s International Resource Panel; Janez Potocnik , Co-chair of the UN’s International Resource Panel and Matti Lievonen , Managing director of Neste.
The organisers of the WCEF2017 are Sitra, the Nordic Council of Ministers, the Ministry of the Environment and the Ministry of Economic Affairs and Employment in cooperation with the following institutions: European Commission, European Environment Agency (EEA), International Institute for Sustainable Development (IISD), Koli Forum, United Nations Environment Programme (UNEP), World Business Council for Sustainable Development (WBCSD) and World Resources Forum (WRF).
Website of the event www.wcef2017.com
Sitra is a future fund that collaborates with partners from different sectors to research, trial and implement bold new ideas that shape the future. Our aim is a Finland that succeeds as a pioneer in sustainable well-being.
View source version on businesswire.com: http://www.businesswire.com/news/home/20161024005743/en/
Contact:
Sitra
Hanna-Leena Ottelin, Specialist
hanna-leena.ottelin(at)sitra.fi
+358
(0)50 376 9499
or
Kari Herlevi, Senior Lead
kari.herlevi(at)sitra.fi
+358
(0)50 463 9397
or
Samuli Laita, Communications
samuli.laita(at)sitra.fi
+358
(0)40 536 8650
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sun Pharma signs Definitive Agreement to Acquire Organon27.4.2026 01:51:00 CEST | Press release
Organon stockholders to receive US$ 14.00 per share in cashThe deal values Organon at EV of US$ 11.75 billionCombined Business leverages complementary portfolios and global scale for sustained long‑term value creation Sun Pharmaceutical Industries Limited(Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) (together with its subsidiaries and/or associated companies, “Sun Pharma”) and Organon & Co. (NYSE: OGN) (“Organon”) today announced that they have entered into a definitive agreement under which Sun Pharma will acquire all outstanding shares of Organon for US$ 14.00 per share in an all‑cash transaction with an enterprise valuation of US$ 11.75 billion. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260426881370/en/ Organon is a global healthcare company formed through a spinoff from Merck, known as MSD outside of the United States and Canada, in 2021. Organon has a legacy of deep trust and strong brand equit
Andersen Global udvider sin tilstedeværelse i Afrika med lanceringen af medlemsfirma i Cameroun26.4.2026 20:56:00 CEST | Pressemeddelelse
Andersen Global træder ind på det camerounske marked, idet Phoenix Advisory bliver medlemsfirma og overgår til Andersen-brandet. Andersen in Cameroun er et specialiseret rådgivningsfirma, der leverer strategiske, erhvervsmæssige, finansielle og operationelle rådgivningsydelser til organisationer i forskellige vækstfaser. Firmaet er grundlagt af fagfolk med erfaring fra store internationale organisationer og kombinerer et stærkt lokalt og centralafrikansk funderet kendskab til forretningsmæssige, juridiske og skattemæssige regler med en skræddersyet tilgang, der har til formål at skabe konkrete og målbare resultater for klienterne. "Overgangen til Andersen-brandet afspejler vores engagement i at vokse sammen med vores kunder og imødekomme stadig mere komplekse behov," udtalte administrerende partner Albert Désiré Zang. "Vi tror på, at langsigtet succes skabes gennem tillid, kvalitet og vedvarende support. At blive et medlemsfirma styrker vores evne til at levere gennemtænkte, bæredygtig
PMCOrganometallix Announces Price Increase on All Products24.4.2026 22:55:00 CEST | Press release
Due to significant changes in market conditions, PMC Organometallix, Inc. announces that effective May 1, 2026, or as contracts permit, prices across all product lines globally will increase by 10-25%. This adjustment is driven by sustained cost pressures from key inputs including rising raw material costs and escalating freight and logistics expenses. While the company has been absorbing these increases, the current economic environment brought on by the geopolitical crisis of the Iran conflict requires this adjustment to continue providing the high-quality, consistent materials and supply reliability that customers expect. PMC Organometallix will implement these changes in a transparent, collaborative manner and values your partnership while navigating these economic challenges. Customers with questions or to discuss a specific situation should contact their account representative. About PMC Group PMC Group is a growth-oriented, diversified, global chemicals and plastics company deli
Frankfurt Higher Regional Court upholds BESREMi® arbitral award in favor of AOP Health24.4.2026 18:52:00 CEST | Press release
Today, the Higher Regional Court of Frankfurt upheld the February 20251 partial final ICC arbitral award in favor of AOP Orphan Pharmaceuticals GmbH (“AOP Health”) in its dispute with PharmaEssentia Corp. (“PharmaEssentia”). The ruling confirms the award which found the Taiwanese company to be liable for certain damages. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260424005227/en/ Portrait Dr. Rudolf Widmann, Founder AOP Health Credit: AOP Health/Daniel Ospelt Dr. Rudolf Widmann, one of the two founders of AOP Health, explains: “We very much welcome the Frankfurt Higher Regional Court’s decision that confirms our position. In the interest of our patients, we are dedicated to maintaining stable and sustainable access to BESREMi® and to responsibly navigating future challenges.” The Product in Dispute The conflict centers around BESREMi® (ropeginterferon alfa-2b), a product launched in 2019 and developed by AOP Health into
Compass Pathways Announces FDA Granted NDA Rolling Review Request and Awarded Commissioner's National Priority Voucher24.4.2026 16:37:00 CEST | Press release
Compass is the most advanced company in classic psychedelics and has generated positive data from two ongoing large, well controlled Phase 3 clinical trials, designed to uphold the highest regulatory standardsFDA grants Compass NDA rolling submission and review request, based on Phase 3 dataCNPV awarded for COMP360, Compass’ proprietary formulation of synthetic psilocybin, for treatment-resistant depression (TRD)CNPV further accelerates momentum and Compass is confident and ready to deliver for patients Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the U.S. Food and Drug Administration (FDA) granted Compass NDA rolling review request and selected COMP360, Compass’ proprietary formulation of synthetic psilocybin, for the Commissioner's National Priority Voucher (CNPV) program for treatment-resistant depression (TRD). Companies selected for the voucher program will be en
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom